Progress in Pediatric Cardiology
Volume 26, Issue 1 , Pages 3-9 , January 2009

Indications for heart transplantation in children

  • Charles B. Huddleston

      Affiliations

    • Corresponding Author Information#1 Children's Place, Suite 5S 50, St. Louis, MO 63110, United States. Tel.: +1 314 454 6165; fax: +1 314 454 2381.

References 

  1. Kantrowitz A, Huller JD, Joos H, Cerruti MM, Carstensen HE. Transplantation of the heart in an infant and an adult. Am J Cardiol. 1968;22:782–790
  2. Triepp RB. A decade of human heart transplantation. Transplant Proc. 1979;11:285–292
  3. Bailey LL, Nehlsen-Cannarella SL, Concepcion W, Jolley WB. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA. 1985;254:3321–3329
  4. Tibballs J, Kawahira Y, Carter BG, Donath S, Brizard C, Wildinson J. Outcomes of surgical treatment of infants with hypoplastic left heart syndrome: an institutional experience 1983–2004. J Pediatr Child Health. 2007;43:746–751
  5. Gordon BM, Rodriguez S, Lee M, Chang RK. Decreasing number of deaths of infants with hypoplastic left heart syndrome. J Pediatr. 2008;153:354–358
  6. Aurora P, Boucek MM, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation report—2007. J Heart Lung Transplant. 2007;26:1223–1228
  7. Organ Procurement and Transplantation Network web page: http://www.optn.org/latestData/rptData.asp
  8. Lipshultz SE. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol. 2000;12:1–28
  9. Tsirka AE, Trinkaus K, Chen SC, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol. 2004;44:391–397
  10. van Beek E, Backx A, Singh S. Cardiac resynchronization as therapy for congestive cardiac failure in children dependent on chronic cardiac pacing [see comment]. [Case reports. Journal article]. Cardiol. Young. 2006;16:187–189
  11. Lee KJ, McCrindle BW, Bohn DJ. Clinical outcomes of acute myocarditis in childhood. Heart. 1999;82:226–233
  12. Connuck DM, Sleeper LA, Colan SD. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008;155:998–1005
  13. Asaumi Y, Yasuda S, Morii I. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26:2185–2192
  14. Duncan BW, Bohn EJ, Atz AM, et al. Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg. 2001;122:440–448
  15. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690–695
  16. Lee KJ, McCrindle BW, Bohn DJ. Clinical outcomes of acute myocarditis in childhood. Heart. 1999;82:226–233
  17. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Sem Oncol. 1998;25(suppl 10)):72–85
  18. Minotti G, Menna P, Salvatoralli E. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229
  19. Ladas EJ, Jacobson JS, Kennedy DD. Antioxidants and cancer therapy: a systematic review. J Clin Oncol. 2004;22:517–528
  20. Marty M, Espio M, Llambart A. Multi-center randomized phase III study of the cardioprotective effect of dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17:614–622
  21. Towbin JA, Lowe AM, Colan SD. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867–1876
  22. Nugent AW, Daubeney PEF, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348:1639–1646
  23. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children. Circulation. 2007;115:773–781
  24. Lipshultz SE, Orav EJ, Towbin JA, et al. Outcome predictors in pediatric hypertrophic cardiomyopathy. Circulation. 2004;110(Suppl III):III–442
  25. Katzin LW, Amato AA. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. J Clin Neuromusc Dis. 2008;9:421–431
  26. Russo LM, Webber SA. Idiopathic restrictive cardiomyopathy in children. Heart. 2005;91:1199–1202
  27. Chen JM Davies RR, Mital SR, et al. Trends and outcomes in transplantation for complex congenital heart disease: 1984 to 2004. Ann Thorac Surg. 2004;78:1352–1361
  28. Helton JG, Aglira BA, Chin AJ, Murphy JD, Pigott JD, Norwood WI. Analysis of potential anatomic or physiologic determinants of outcome of palliative surgery for hypoplastic left heart syndrome. Circulation. 1986;74:170–176
  29. Sade RM, Crawford FA, Fyfe DA. Symposium on hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 1986;91:937–939
  30. Bailey LL, Gundry SR, Razzouk AJ, Wang N, Sciolaro CM, Chiavarelli M. Bless the babies: one hundred fifteen late survivors of heart transplantation during the first year of life. The Loma Linda University Pediatric Heart Transplant Group. J Thorac Cardiovasc Surg. 1993;105:805–814
  31. Mahle WT, Spray TL, Wernovsky G, et al. Survival after reconstructive surgery for hypoplastic left heart syndrome. A 15-year experience from a single institution. Circulation. 2000;102(suppl III):III136–41
  32. Tweddel JS, Hoffman GM, Mussatto K, et al. Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation. 2002;106(suppl I):I182–189
  33. Calder AL, Peebles CR, Occleshaw CJ. The prevalence of coronary arterial abnormalities in pulmonary atresia with intact ventricular septum and their influence on surgical results. Card Young. 2007;17:387–396
  34. Fenton KN, Pigula FA, Gandhi SK, Russo L, Duncan KF. Interim mortality in pulmonary atresia with intact ventricular septum. Ann Thorac Surg. 1998;78:1994–1998
  35. Ekman-Joelsson BM, Berggren H, Boll AM, Sixt R, Sunnegardh J. Abnormalities in myocardial perfusion after surgical correction of pulmonary atresia with intact ventricular septum. Card Young. 2008;18:89–95
  36. Sarris GE, Giannopoulos NM, Tsoutsinos AJ, et al. Results of surgery for Ebstein anomaly: a multicenter study from the European Congenital Heart Surgeons Association. J Thorac Cardiovasc Surg. 2006;132:50–57
  37. Linn JSL, McCrindle BW, Smallhorn JF, et al. Clinical features, management, and outcome of children with fetal and postnatal diagnoses of isomerism syndromes. Circulation. 2005;112:2454–2461
  38. Larsen RL, Eguchi JH, Mulla NF, et al. Usefulness of cardiac transplantation in children with visceral heterotaxy (asplenic and polysplenic syndromes and single right-sided spleen with levocardia) and comparison of results with cardiac transplantation in children with dilated cardiomyopathy. Am J Cardiol. 2002;89:1275–1279
  39. Nollert G, Fischlein T, Bouterwek S, Bohmer C, Klinner W, Reichart B. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol. 1997;30:1374–1383
  40. Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993;329:593–599
  41. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, et al. Decline in ventricular function and clinical condition after Mustard repair for transposition of the great arteries (a prospective study of 22–29 years). Eur Heart J. 2004;25:1264–1270
  42. Moons P, Gewillig M, Sluysmans T, et al. Long term outcome up to 30 years after the Mustard or Senning operation: a nationwide multicentre study in Belgium. Heart. 2004;90:307–313
  43. Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation. 2006;114:273–280
  44. Mitchell MB, Campbell DN, Ivy D, et al. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg. 2004;128:693–702
  45. Bisleri G, Morgan JA, Deng MC, Mancini DM, Oz MC. Should HIV-positive recipients under go heart transplantation?. J Thorac Cardiovasc Surg. 2003;126:1639–1640
  46. Kirklin JK, Naftel DC, McGiffin DC McVay RF, Blackstone EH, Karp RB. Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol. 1988;11:917–924
  47. Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg. 2007;83:1697–1705
  48. Huddleston CB. Pediatric heart transplantation. In:  Kaiser LR,  Kron IL,  Spray TL editor. Mastery of cardiothoracic surgery. Philadelphia: Lippincott Williams & Wilkins; 2007;p. 973–984
  49. Canter C, Naftel D, Caldwell R, et al. Survival and risk factors for death after cardiac transplantations in infants. A multi-institutional study. The Pediatric Heart Transplant Study. Circulation. 1997;96:227–231

PII: S1058-9813(08)00065-9

doi: 10.1016/j.ppedcard.2008.10.003

Progress in Pediatric Cardiology
Volume 26, Issue 1 , Pages 3-9 , January 2009

Article Tools

* Image Usage & Resolution